hiPS Derived Assay for Screening Hematopoietic Differentiation Toxicant Effects

Primorigen生物科学(R)摘要 Primorigen Biosciences将利用SBIR资金开发一种新的商业分析方法， 测定化合物对人诱导多能干细胞的毒性 诱导分化为造血祖细胞及其分化的造血祖细胞 HiPSCs。 该分析将依赖Primorigen的高效、正在申请专利的MesoTotal“培养基来进行 将HiPSCs分化为HPC。 第一阶段研究将优化高通量筛选的HPC区分和分析 格式，确定化合物对hPSCs分化为HPC的毒性影响，以及 筛选对造血祖细胞有毒性的化合物 臀部细胞。在第二阶段，我们会加强商业应用，包括：a)把系统改装成 384-良好的HTS格式，b)通过包括更多的HiPSC系来增加遗传多样性，c) 测试更大的资料库和指示典型环境暴露的混合物，以及d) 完成二次筛选，以确定给药效果和作用机制。在……里面 第三阶段，将对测试系统进行潜在的药物开发评估 申请。 商业应用是一种健壮的、可扩展的人体检测系统，用于筛查和评估 对HIPS细胞分化为HPC的复合毒性。

Primorigen Biosciences (R) Abstract Primorigen Biosciences will use SBIR funds to develop a novel commercial assay that measures the toxicity of compounds on human induced pluripotent stem cells (hiPSCs) differentiating into hematopoietic progenitor cells (HPCs) and on HPCs differentiated from hiPSCs. The assay will rely on Primorigen's highly efficient, patent-pending MesoTotal" medium for differentiating hiPSCs into HPCs. Phase I studies will optimize HPC differentiation and analysis for high-throughput screening formats, determine toxic impact that compounds have on hiPSCs differentiating into HPCs, and screen for compounds that exhibit toxicity towards hematopoietic progenitor cells derived from hiPS cells. In Phase II, we will enhance commercial applications by a) adapting the system to 384-well HTS formats, b) increasing genetic diversity by including additional hiPSC lines, c) testing a larger library and mixtures indicative of typical environmental exposure, and d) completing secondary screenings to establish dosing efficacy and mechanism of actions. In Phase III, the assay system will be evaluated for potential pharmaceutical development applications. The commercial application is a robust scalable human assay system for screening to assess compound toxicity against hiPS cells differentiating into HPCs.